Ignite Creation Date:
2025-12-25 @ 2:29 AM
Ignite Modification Date:
2025-12-31 @ 10:50 AM
Study NCT ID:
NCT06987734
Status:
RECRUITING
Last Update Posted:
2025-06-26
First Post:
2025-05-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-06-19
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-05-16
First Submit QC Date:
None
Study First Post Date:
2025-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-21
Last Update Post Date:
2025-06-26
Last Update Post Date Type:
ACTUAL